Incidence studies

Latest Articles

Article
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
Lana Zhovtis Ryerson, John Foley, Ih Chang, et al.

Neurology September 12, 2019
Editorial
Do good things come to those who wait?Dosing interval of natalizumab in MS
David B. Clifford, Kenneth L. Tyler

Neurology September 12, 2019
Article
Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology
Elia Sechi, Eslam Shosha, Jonathan P. Williams, et al.

Neurology June 24, 2019
Research
Factors associated with 30-day readmission for patients hospitalized for seizures
Samuel W. Terman, Elan L. Guterman, Chloe E. Hill, et al.

Neurology: Clinical Practice July 12, 2019